(Q30410899)

21 June 2017

Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives (English)

1 reference

21 June 2017

0 references

0 references

Aeron C Hurt

1

0 references

David Shu-cheong Hui

object named as

David S Hui

8

0 references

Timothy M. Uyeki

15

object named as

Timothy M Uyeki

1 reference

21 June 2017

5

Alicia M Fry

1 reference

21 June 2017

7

Frederick G Hayden

1 reference

21 June 2017

16

Maria Zambon

1 reference

21 June 2017

6

Larisa V Gubareva

1 reference

21 June 2017

10

Angie Lackenby

1 reference

21 June 2017

3

Nancy J Cox

1 reference

21 June 2017

4

Rod Daniels

1 reference

21 June 2017

14

Masato Tashiro

1 reference

21 June 2017

12

Adam Meijer

1 reference

21 June 2017

Tawee Chotpitayasunondh

2

1 reference

21 June 2017

Olav Hungnes

9

1 reference

21 June 2017

Wilina Lim

11

1 reference

21 June 2017

Charles Penn

13

1 reference

21 June 2017

WHO Consultation on Pandemic Influenza A (H1N1) 2009 Virus Resistance to Antivirals

17

1 reference

21 June 2017

language of work or name

1 reference

18 December 2011

1 reference

Lancet Infectious Diseases

21 June 2017

1 reference

21 June 2017

12

1 reference

21 June 2017

3

1 reference

21 June 2017

240-248

1 reference

Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro

21 June 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Oral oseltamivir treatment of influenza in children.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Resistant influenza A viruses in children treated with oseltamivir: descriptive study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Frequency of drug-resistant viruses and virus shedding in pediatric influenza patients treated with neuraminidase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Influenza virus neuraminidase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Oseltamivir resistance and the H274Y neuraminidase mutation in seasonal, pandemic and highly pathogenic influenza viruses.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Widespread oseltamivir resistance in influenza A viruses (H1N1), South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Structural basis for oseltamivir resistance of influenza viruses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Permissive secondary mutations enable the evolution of influenza oseltamivir resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Monitoring and characterization of oseltamivir-resistant pandemic (H1N1) 2009 virus, Japan, 2009-2010.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Oseltamivir-resistant pandemic A(H1N1) 2009 influenza viruses detected through enhanced surveillance in the Netherlands, 2009-2010.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Detection of an oseltamivir-resistant pandemic influenza A/H1N1 virus in Hong Kong

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Community-acquired oseltamivir-resistant pandemic (H1N1) 2009 in child, Israel

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Pandemic (H1N1) 2009 and oseltamivir resistance in hematology/oncology patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Evidence of person-to-person transmission of oseltamivir-resistant pandemic influenza A(H1N1) 2009 virus in a hematology unit.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

A community cluster of oseltamivir-resistant cases of 2009 H1N1 influenza

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Oseltamivir-resistant pandemic H1N1/2009 influenza virus possesses lower transmissibility and fitness in ferrets

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Oseltamivir-resistant pandemic A/H1N1 virus is as virulent as its wild-type counterpart in mice and ferrets

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Characterization of oseltamivir-resistant 2009 H1N1 pandemic influenza A viruses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Oseltamivir-resistant variants of the 2009 pandemic H1N1 influenza A virus are not attenuated in the guinea pig and ferret transmission models.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Multidrug-resistant 2009 pandemic influenza A(H1N1) viruses maintain fitness and transmissibility in ferrets

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Establishment of multiple sublineages of H5N1 influenza virus in Asia: Implications for pandemic control

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

A single base-pair change in 2009 H1N1 hemagglutinin increases human receptor affinity and leads to efficient airborne viral transmission in ferrets

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

A computational-experimental approach identifies mutations that enhance surface expression of an oseltamivir-resistant influenza neuraminidase

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Recovery of a multidrug-resistant strain of pandemic influenza A 2009 (H1N1) virus carrying a dual H275Y/I223R mutation from a child after prolonged treatment with oseltamivir

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Reduced effectiveness of oseltamivir in children infected with oseltamivir-resistant influenza A (H1N1) viruses with His275Tyr mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Clinical effectiveness of oseltamivir for influenza A(H1N1) virus with H274Y neuraminidase mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

A two-year survey of the oseltamivir-resistant influenza A(H1N1) virus in Yamagata, Japan and the clinical effectiveness of oseltamivir and zanamivir

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Direct measurement of the anti-influenza agent zanamivir in the respiratory tract following inhalation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus infection in children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Oseltamivir-resistant pandemic (H1N1) 2009 influenza in a severely ill patient: the first Australian case.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Mixtures of oseltamivir-sensitive and -resistant pandemic influenza A/H1N1/2009 viruses in immunocompromised hospitalized children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

A comparison of pyrosequencing and neuraminidase inhibition assays for the detection of oseltamivir-resistant pandemic influenza A(H1N1) 2009 viruses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Pyrosequencing as a tool to detect molecular markers of resistance to neuraminidase inhibitors in seasonal influenza A viruses.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Detection of molecular markers of drug resistance in 2009 pandemic influenza A (H1N1) viruses by pyrosequencing.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Minority variants of drug-resistant HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Zanamivir-resistant influenza viruses with a novel neuraminidase mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Characteristics of patients with oseltamivir-resistant pandemic (H1N1) 2009, United States

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Emergence of intratreatment resistance to oseltamivir in pandemic influenza A H1N1 2009 virus.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Emergence of oseltamivir-resistant pandemic (H1N1) 2009 virus within 48 hours

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Respiratory failure caused by 2009 novel influenza A/H1N1 in a hematopoietic stem-cell transplant recipient: Detection of extrapulmonary H1N1 RNA and use of intravenous peramivir

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Failure of combination oral oseltamivir and inhaled zanamivir antiviral treatment in ventilator- and ECMO-treated critically ill patients with pandemic influenza A (H1N1)v

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Evaluation of the antiviral response to zanamivir administered intravenously for treatment of critically ill patients with pandemic influenza A (H1N1) infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Intravenous zanamivir for oseltamivir-resistant 2009 H1N1 influenza

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Use of intravenous zanamivir after development of oseltamivir resistance in a critically Ill immunosuppressed child infected with 2009 pandemic influenza A (H1N1) virus.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Severe H1N1-associated acute respiratory failure in immunocompromised children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

H275Y mutant pandemic (H1N1) 2009 virus in immunocompromised patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Atypical clinical presentation of H1N1 influenza in a dialysis patient.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Prolonged influenza virus infection during lymphocytopenia and frequent detection of drug-resistant viruses.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Cluster of oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infections on a hospital ward among immunocompromised patients--North Carolina, 2009

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Possible transmission of pandemic (HIN1) 2009 virus with oseltamivir resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Epidemiology, prevention, and management of influenza in patients with hematologic malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

Guidance on novel influenza A/H1N1 in solid organ transplant recipients.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970318-8

7 January 2021

10.1016/S1473-3099(11)70318-8

Identifiers

DOI

1 reference

21 June 2017

1 reference